Early Phase 1 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been diagnosed with multiple myeloma (a type of blood cancer) confirmed using standard international guidelines, and whose cancer cells show a specific protein called BCMA, detected by laboratory testing
• People who have already received at least 2 separate rounds of treatment for multiple myeloma, with at least one full treatment cycle completed for each round, and whose cancer has come back or worsened within 12 months of their most recent treatment — or whose cancer did not respond to two specific types of treatment (immunomodulatory drugs and proteasome inhibitors) and worsened within 2 months of their last treatment
• People whose cancer is still detectable at the time of screening, based on specific measurable levels of certain proteins in the blood or urine, or abnormal levels of specific components in the blood
• People who are reasonably well and active in daily life (rated on a standard scale from 0 to 2), with a life expectancy of at least 3 months
• People whose bone marrow is producing enough blood cells at screening, including adequate levels of red blood cells, white blood cells, platelets, and specific immune cells, as measured by blood tests
• People whose kidneys are functioning adequately, with a kidney filtration rate of at least 45 mL/min
• People whose liver function test results are within acceptable ranges at screening
• People whose heart is functioning adequately, including a heart pumping strength of at least 40%, no significant fluid around the heart, and no significant abnormalities on a heart tracing test
• People whose lungs are functioning adequately, with blood oxygen levels of at least 90% and no significant fluid around the lungs
• Women who could become pregnant must have a negative pregnancy test at screening and before receiving the study drug, and must not be breastfeeding
• People who could father or become pregnant must agree to use effective contraception from the time of signing consent until 1 year after receiving the study drug
• People who could father or become pregnant must agree not to donate sperm, eggs, or other reproductive material from the time of signing consent until 1 year after receiving the study drug
• People (or their legal representative) who are willing and able to provide written consent, showing they understand the study and agree to take part

Who may not be able to join:

• People who have recently received certain cancer treatments, including targeted therapies, experimental drugs, immune-based or other systemic treatments, chemotherapy, or radiation therapy, within specific timeframes before joining (the exact timeframe depends on the type of treatment — confirm with trial site)
• People who have received a stem cell transplant using donor cells within the past 6 months, or their own stem cells within the past 3 months
• People who have or have had another type of cancer, unless it was fully treated with no signs of return for at least 2 years before joining, or was a type of skin cancer (non-melanoma) that was adequately treated with no signs of return
• People who have previously received a specific type of experimental virus-based therapy (using VSVG pseudotype virus)
• People who have a serious, uncontrolled infection at the time of screening (such as a bacterial, viral, or fungal infection)
• People who have certain active or uncontrolled viral infections, including active hepatitis B, active hepatitis C, HIV, or syphilis, based on blood test results
• People with serious heart conditions, including severe heart failure, a heart attack or certain heart procedures within the past 6 months, significant irregular heartbeats, unexplained loss of consciousness (not due to dehydration or a simple fainting episode), or a significant history of heart muscle disease
• People with certain other serious medical conditions, including a primary immune system disorder, a stroke or seizures within the past 6 months, clear signs of dementia or confusion, or a history of Parkinson's disease
• People who have had surgery within 2 weeks before treatment or who have surgery planned within 2 weeks after treatment (except for minor procedures done under local anaesthetic)
• People who have received a live vaccine within 1 month before treatment
• People with a known severe allergic reaction to the study drug (ESO-T01) or any of its ingredients
• People with a known severe allergic reaction to a medication called Tocilizumab
• People who are unable to have a suitable vein accessed for the infusion
• People who, in the treating doctor's judgement, have any other condition that makes participation in the study unsuitable

Important: Always verify eligibility with the trial site directly before applying.